Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Lipoic Acid-Intervened Decellularized Stem Cell Spheroid-Based Injectable Granular Gel for Diabetic Tissue Regeneration.

Wang T., Fang H., Qi L., Myoungseop S., Khan A., Gong L.

Animal Study on Immune Modulation, published in Adv Sci (Weinh) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Adv Sci (Weinh) (2026)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
41944333
DOI
10.1002/advs.202521924

Abstract (original English)

Advancements in tissue engineering have revolutionized therapeutic paradigms for diabetic tissue defects; however, the lack of applicable scaffold containing various bioactive substance aggregates remained a critical bottleneck hindering satisfactory repair effect. In this study, adipose-derived stem cells (ADSCs) were functionally re-engineered using lipoic acid (LA) to fabricate a novel LA-intervened stem cell spheroid (LA-SCS) with enhanced paracrine activity and extracellular matrix (ECM) biosynthetic capacity. Subsequent decellularization mitigated immunogenicity, yielding LA-intervened decellularized stem cell spheroid (LA-dSCS). In vitro assays confirmed its immunomodulatory potency, as evidenced by the activation of signaling cascades associated with macrophage reprogramming, homeostasis, and autophagy. Furthermore, leveraging the intrinsic viscoelastic properties of the LA-dSCS, a convenient preparation method for preparing LA-dSCS derived injectable material was established, wherein LA-dSCS micro-particles assemble into LA-dSCS granular gel. In vivo studies using diabetic rat models demonstrated closure of both wound and cranial defects. Collectively, this study established a biomimetic engineering strategy that integrates cell-free bioactive aggregates with injectable granular gels, offering a novel proof‑of‑concept strategy for the regeneration of complex diabetic t

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsThioctic AcidRatsStem CellsTissue EngineeringSpheroids, CellularDiabetes Mellitus, ExperimentalRegenerationTissue ScaffoldsGels

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research